Table 3:
Analysis of overall survival predictors by histology categories of thymic malignancies (thymoma, thymic carcinoma and NETT). Cox proportional hazard model with shared frailty
| Thymoma WHO A-AB-B1 |
Thymoma WHO B2-B3 |
NETT |
Thymic carcinoma |
Interaction, P | |||||
|---|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | ||
| Age (continuous, per 5 years increase) | 1.22 (1.13–1.32) | <0.001 | 1.17 (1.09–1.26) | <0.001 | 1.15 (0.92–1.45) | 0.220 | 1.18 (1.09–1.29) | <0.001 | 0.852 |
| Male | 1.62 (1.11–2.38) | 0.013 | 1.00 (0.69–1.46) | 0.987 | 1.54 (0.39–6.07) | 0.540 | 1.18 (0.73–1.89) | 0.502 | 0.345 |
| Myasthenia gravis | 1.19 (0.76–1.85) | 0.446 | 1.07 (0.72–1.60) | 0.734 | 1.99 (0.26–15.41) | 0.507 | 0.99 (0.49–1.98) | 0.975 | 0.903 |
| Tumour size (per 1 cm increase) | 1.06 (0.98–1.14) | 0.135 | 1.05 (0.97–1.14) | 0.199 | 1.01 (0.84–1.21) | 0.957 | 1.02 (0.92–1.13) | 0.699 | 0.899 |
| Masaoka stage | |||||||||
| 1 (Ref) | 1 | – | 1 | – | 1 | – | 1 | – | 0.690 |
| 2 | 1.32 (0.83–2.11) | 0.243 | 0.78 (0.39–1.56) | 0.480 | 1.12 (0.24–5.29) | 0.883 | 1.07 (0.28–4.11) | 0.921 | |
| 3 | 2.13 (1.23–3.72) | 0.007 | 2.87 (1.59–5.19) | <0.001 | 2.30 (0.31–17.14) | 0.412 | 2.88 (0.82–10.15) | 0.100 | |
| 4 | 4.37 (2.16–8.85) | <0.001 | 5.17 (2.48–10.77) | <0.001 | 4.37 (2.16–8.85) | <0.001 | 3.69 (1.05–13.04) | 0.042 | |
| R status (R1-R2 vs R0) | 1.39 (0.73–2.63) | 0.317 | 1.85 (1.12–3.04) | 0.017 | 1.68 (0.49–5.74) | 0.407 | 1.91 (0.97–3.76) | 0.061 | 0.874 |
NETT: neuroendocrine thymic tumour.